1-3 of 3
Kyle A Beckwith, B.S.
Close
Sort by
Journal Articles

BI 836826, a Novel Fc-Engineered Antibody in Combination with Phosphoinositide-3-Kinase Inhibitor for Treatment of High Risk Chronic Lymphocytic Leukemia

Deborah M Stephens, DO, Kyle A Beckwith, B.S., Carolyn Cheney, B.S, Xiaokui Mo, PhD MAS, Joseph M Flynn, D.O., MPH, Jeffrey A. Jones, MD, Kami J. Maddocks, MD, Karl-Heinz Heider, PhD, Natarajan Muthusamy, DVM, PhD, John C. Byrd, MD
Journal: Blood
Blood (2014) 124 (21): 4681.
https://doi.org/10.1182/blood.V124.21.4681.4681
Published: 2014
Journal Articles

A Transgenic Mouse Model of Aggressive B-Cell Malignancy for Evaluating Anti-Human CD37 Therapeutics

Kyle A Beckwith, B.S., Frank W Frissora, M.S., Matthew R Stefanovski, B.S., Jutta Deckert, Ph.D., Carlo M Croce, M.D., Xiaokui Mo, PhD, David Jarjoura, PhD, John C. Byrd, MD, Natarajan Muthusamy, DVM, Ph.D
Journal: Blood
Blood (2012) 120 (21): 188.
https://doi.org/10.1182/blood.V120.21.188.188
Published: 2012
Journal Articles

Ibrutinib Is an Irreversible Molecular Inhibitor of Interleukin-2 Inducible Kinase: Expanding Therapeutic Potential and Modulating a Th1 Selective Pressure in CD4 T-Cells

Jason A Dubovsky, Ph.D, Kyle A Beckwith, B.S., Jennifer A. Woyach, MD, Samantha M. Jaglowski, MD, MPH, Joshua Hessler, Betty Y. Chang, PhD, Karilyn Larkin, Matthew R Stefanovski, B.S., Frank W Frissora, M.S., Lisa L. Smith, Kelly A Smucker, Joseph M. Flynn, DO, MPH, Jeffrey A. Jones, MD, MPH, Leslie A Andritsos, MD, Kami Maddocks, MD, Amy Lehman, Richard R. Furman, MD, Jeff Sharman, MD, Anjali Mishra, Ph.D., Michael A. Caligiuri, M.D., Joseph J. Buggy, PhD, Natarajan Muthusamy, DVM, Ph.D, Amy J Johnson, PhD, John C. Byrd, MD
Journal: Blood
Blood (2012) 120 (21): 775.
https://doi.org/10.1182/blood.V120.21.775.775
Published: 2012